Targeting the ICAM-1/LFA-1 adhesion axis attenuates lethal Crimean-Congo hemorrhagic fever virus infection Authors: Yajie Liu, Liushuai Li, Kai Liu, Shuo Chen, Fan Wu, Jiang Li, Xinbo Zhou, Zhihong Hu, Wu Zhong, Manli Wang Published: 2026 ABSTRACT AbstractCrimean-Congo hemorrhagic fever virus (CCHFV) is a highly pathogenic tick-borne bunyavirus. Infection and dysfunction of the vascular endothelium are likely key factors in CCHFV pathogenesis, yet the underlying mechanisms remain poorly understood. Using a mouse model, we demonstrated that CCHFV directly infects vascular endothelium, leading to marked activation and damage, as evidenced by the upregulation of adhesion molecules. To further investigate this phenomenon, we performed a quantitative proteomics study on CCHFV-infected human umbilical vein endothelial cells (HUVECs), confirming a significant upregulation of cell adhesion molecular pathways. Notably, the key adhesion molecule intercellular adhesion molecule 1 (ICAM-1) was prominently induced upon infection, which was transcriptionally dependent on NF-κB. ICAM-1 interacts with its receptor integrin (LFA-1) on leukocytes to mediate firm adhesion and transmigration, thereby driving inflammatory responses. Using an established in vitro adhesion assay, we found that CCHFV infection robustly increased the adhesion of Jurkat T cells to HUVECs. This enhanced adhesion was specifically dependent on ICAM-1, as it was substantially reduced by knockdown of ICAM1 or by competition with its soluble extracellular domain. Moreover, lifitegrast—an approved anti-inflammatory small-molecule antagonist that selectively blocks ICAM-1/LFA-1 interaction, significantly inhibited CCHFV-induced Jurkat T cell adhesion. Importantly, in a lethal murine model of CCHFV infection, the treatment with lifitegrast sodium improved survival rates and concurrently alleviated leukocyte infiltration and tissue damage. These findings delineate an ICAM-1-mediated mechanism of vascular activation and inflammation in CCHFV infection and highlight a promising anti-inflammatory-based strategy for treating CCHF.Keywords: Crimean-Congo hemorrhagic fever, Vascular endothelium activation, ICAM-1 upregulation, Endothelial–leukocyte adhesion, Lifitegrast, Therapeutic intervention Introduction Crimean-Congo hemorrhagic fever (CCHF) is a fatal disease caused by infection with the Crimean-Congo hemorrhagic fever virus (CCHFV), a highly-pathogenic tick-borne bunyavirus. With cases reported in over 30 countries worldwide, CCHF poses a significant global health threat (Belobo et al., 2021; Ergönül, 2006; Fereidouni et al., 2025). The clinical symptoms of CCHF include fever, hemorrhage, inflammatory storm, and multiple organ failure, with an average case fatality of 40% (Elaldi et al., 2009; Swanepoel et al., 1989; Whitehouse, 2004). Research into the pathogenesis mechanisms of CCHFV has been severely constrained by the requirement for biosafety level-4/3 facilities, a major barrier to therapeutic development. In response to its high mortality and epidemic potential, the World Health Organization (WHO) has designated CCHFV as a priority pathogen requiring urgent research and countermeasure development (Mehand et al., 2018). Clinical and animal model studies suggest that CCHFV infection is frequently associated with hemorrhage, endothelial dysfunction and immune dysregulation. In a clinical analysis of 50 CCHF cases, the fatal patients showed severely abnormal levels of activated partial thromboplastin time, thrombin time, and fibrin degradation products, indicating disseminated intravascular coagulopathy (DIC). Notably, fatal outcomes were closely linked to severe DIC (Swanepoel et al., 1989). Further pathological evidence from post-mortem liver revealed CCHFV antigen-positive cells within the hepatic sinusoidal endothelium, suggesting the direct vascular endothelium involvement (Burt et al., 1997). Additional clinical investigation showed that serum soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) were markedly increased in severe CCHF patients and correlated with disease severity and prognosis (Bodur et al., 2010; Ozturk et al., 2010). This evidence supports the potential role of endothelial activation and dysfunction in the pathogenesis of CCHFV, given that the upregulation of sICAM-1 and sVCAM-1 is a classic feature of endothelial cell activation (Videm & Albrigtsen, 2008). Moreover, elevated serum inflammatory factors—including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interferon-γ (IFN-γ), interleukin-10 (IL-10)—were associated with the progression of the disease (Bente et al., 2010; Ergonul et al., 2006; Papa et al., 2006; Saksida et al., 2010). Cytokine storms may also further exacerbate endothelial cell activation and DIC. Together, these findings highlight the crucial role of vascular injury in CCHF progression. Nevertheless, the key molecular drivers of these processes and potential therapeutic targets remain to be elucidated. The activation of vascular endothelium represents a common pathological hallmark in hemorrhagic fever virus infections, characterized by a shift in endothelial phenotype from homeostasis to a pro-adhesive and pro-inflammatory state (Akinci et al., 2013; Connolly-Andersen et al., 2011). Once activated, endothelial cells modulate innate and adaptive immune responses by regulating the transmigration of leukocytes from the bloodstream into surrounding tissues (Vestweber, 2007). This process involves the upregulation of multiple cell adhesion molecules (such as selectins, ICAM-1, VCAM-1), which drive the leukocyte adhesion cascade from "rolling" to "firm adhesion" and ultimately to "transendothelial migration" (Butcher, 1991; Springer, 1994). The early rolling adhesion is reversible and unstable (Vestweber & Blanks, 1999). Subsequently, the binding of leukocyte integrins (e.g., LFA-1, VLA-4) to endothelial adhesion molecules (e.g., ICAM-1, VCAM-1) strengthens the interaction into "firm adhesion" and triggers leukocyte transendothelial migration along with inflammatory signaling (Dustin & Springer, 1988, 1989; Osborn et al., 1989; Springer, 1990). This adhesion cascade critically influences the efficiency of leukocyte recruitment and the extent of tissue damage, highlighting its potential as a key target for anti-inflammatory and immunomodulatory interventions. Notably, previous studies have employed the small molecule inhibitor lifitegrast, which disrupts ICAM-1/LFA-1 interaction, for anti-inflammatory therapy. For example, its efficacy was demonstrated in mouse models of poly(I:C)/D-GalN-induced acute liver injury and Crohn's disease, offering a feasible pharmacological strategy to block the adhesion cascade (Pabois et al., 2024; Sun et al., 2023), although this strategy has not yet been evaluated in the context of viral infectious diseases. In vitro studies have confirmed that CCHFV infection can induce the activation of vascular endothelial cells and result in increased adhesion of isolated leukocytes to the activated endothelium (Connolly-Andersen et al., 2009, 2011). In contrast, evidence for endothelial activation caused by CCHFV infection remains limited in vivo. Furthermore, whether such adhesion is directly mediated by ICAM-1 has not yet been verified. The molecular mechanisms underlying ICAM-1 upregulation also remains unclear. More importantly, the downstream consequences of ICAM-1-driven endothelial activation, as well as the potential therapeutic targets involved, warrant further in-depth exploration. In this study, we demonstrated in vivo that CCHFV directly infects vascular endothelium, inducing its activation and injury, with upregulated adhesion molecules. Quantitative proteomics of CCHFV infected human umbilical vein endothelial cells (HUVECs) revealed global upregulation of the cell adhesion molecules pathway, including marked increase in ICAM-1. As ICAM-1 binds leukocyte integrin LFA-1 to promote lymphocyte adhesion and inflammation, we performed an in vitro adhesion assay using CCHFV infected HUVECs and LFA-1-expressing Jurkat cells. The role of ICAM-1 in mediating adhesion was confirmed by gene knockdown, protein competition, and treatment with specific antagonist lifitegrast. Notably, lifitegrast administration in a lethal CCHFV mouse model improved survival and alleviated pathological injury. Results CCHFV infects and activates vascular endothelial cells in vivo To investigate CCHFV-induced vascular injury, we intravenously challenged IFNAR−/− mice, a lethal infection model, with CCHFV. As illustrated in Fig. 1(A), liver and spleen tissues were collected for viral load quantification, histopathologic examination, and assessment for vascular activation and damage. All infected mice exhibited weight loss by 3 days post infection (dpi) and succumbed between 4 and 6 dpi (100% mortality rate; Fig. S1A). Significant virus replication was detected in both liver and spleen by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and immunofluorescence staining (Fig. S1A and B). Histopathological analysis of infected liver revealed massive inflammatory infiltrates (yellow arrows), hepatocyte coagulative necrosis (black asterisk), extensive steatosis (yellow box), and thrombosis (black arrow), indicating severe liver damage (Fig. S1B). Spleen architecture was also disrupted, with loss of distinct boundary between the white and red pulp (Fig. S1B). Using immunofluorescence co-labeling, we investigated whether CCHFV directly infects vascular endothelial cells in vivo. CCHFV nucleocapsid protein (NP) was found to co-localize with CD31-positive vascular endothelial cells (Fig. 1(B)), indicating that vascular endothelial cells are susceptible to direct CCHFV infection in vivo. CCHFV infects and activates vascular endothelial cells in vivo. (A) Schematic diagram of the animal experiment. IFNAR−/− mice were infected with CCHFV by intravenous injection, and body weight and clinical symptoms were monitored daily. Mice were sacrificed in the near-death stage, and the main target organs (liver and spleen), were collected for viral load detection, histopathological analysis, and vascular activation detection. (B) Liver sections were stained with immunofluorescence to detect vascular endothelial marker CD31 (green) and CCHFV NP antigen (red), and the cell nuclei were marked with Hoechst 33258 (blue). (C) Activation of vascular endothelium in the liver was detected by immunofluorescence. ICAM-1/VCAM-1 (green), CCHFV NP antigen (red), and nuclei (Hoechst 33258, blue). Scale bars are shown in the figures. Since endothelial cell activation is a hallmark of vascular injury, we examined this process in the livers of CCHFV-infected mice. VCAM-1 and ICAM-1 are early markers of vascular endothelial activation and injury; they are constitutively expressed at low levels in resting blood vessels but are highly inducible by viral infection or inflammatory stimuli. Accordingly, the expression of both adhesion molecules was minimal in mock-infected murine livers (Fig. 1(C)). In contrast, CCHFV infection led to significant upregulation of ICAM-1 and VCAM-1, predominantly localized around the hepatic vascular endothelium (yellow arrows) and sinusoidal endothelium (white arrows) (Fig. 1(C)). Furthermore, elevated ICAM-1 expression is associated with increased vascular permeability, and leads to the downregulation or redistribution of tight junction proteins (TJPs), such as tight junction protein 1/2 (ZO-1/ZO-2) and occludin (Clark et al., 2007; Patibandla et al., 2009). In line with this mechanism, we observed that CCHFV infection markedly reduced representative tight junction marker ZO-1 expression in the liver (Fig. S1C). Correspondingly, Evans blue (EB) dye extravasation assay demonstrated that CCHFV infection indeed enhanced vascular permeability (Fig. S1D). These findings demonstrate that CCHFV infection triggers extensive endothelial activation and results in significant damage of vascular barrier. Quantitative proteomics reveals CCHFV-induced upregulation of the cell adhesion molecules pathway To further investigate the mechanisms of infection-induced damage and establish a suitable in vitro model, quantitative proteomic analysis was performed using HUVECs (Fig. 2(A)). Successful infection was confirmed by the increasing viral load and positive immunofluorescence signals for CCHFV NP (Fig. 2(B); Fig. S2A) and identification of viral proteins by mass spectrometry (Fig. 2(C)). Among the three viral proteins, CCHFV NP showed the most pronounced increase across all infection time points (Fig. 2(C) and (D)). Proteomic profiling identified a total of approximately 7 800 host proteins, among which 1 811 were differentially-expressed following infection. The progressive enrichment of both upregulated and downregulated proteins over the course of infection indicated a substantial impact of CCHFV on host cells (Fig. 2(D)). Notably, upregulated host proteins are primarily involved in interferon-mediated antiviral responses, including the members of IFIT and OAS families, as well as MX1 and ISG15 (Fig. 2(D)). Quantitative proteomic analysis of CCHFV-infected HUVECs. (A) Flowchart of quantitative proteomics analysis of CCHFV-infected HUVECs. Two independent biological replicates were set at each time point. Cell samples were subjected to protein extraction, digestion and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis to obtain quantitative proteomics data. (B) Detection of viral load in infected cells at different time points. The results were shown as the mean ± SD. Statistical analysis was performed using one-way ANOVA, followed by Tukey's multiple comparisons test, ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.000 1. (C) Identification of viral protein components in proteomics data. Mass spectrometry analysis identified RdRP, GP and NP of CCHFV. The figure showed the relative ratios at 24, 48 and 72 hpi compared to 0 hpi. (D) Volcano plots of differentially expressed proteins (DEPs) at 24, 48 and 72 hpi compared with the 0 hpi control group. Each dot represents an identified protein. Red dots represent up-regulated proteins, blue dots represent down-regulated proteins, and gray dots represents proteins without significant change. CCHFV NP is highlighted with a circle. Differentially expression was defined as |log2FC| > 0.585 and P value < 0.05. (E) KEGG pathway enrichment analysis of DEPs. Bubble size represents the number of DEPs in that pathway, and the color intensity indicates -log10 (adjusted P) for pathway enrichment. (F) Heatmap of the expression patterns of DEPs in the cell adhesion molecules pathway. The color intensity represents the standardized expression level (Z-score). The DEPs are manually grouped and labeled according to their protein functions. The rows represent proteins, and the columns represent different time points. KEGG pathway analysis revealed significant enrichment in numerous pathways. Among these, the cell adhesion molecules pathway was the most prominent, displaying the highest enrichment significance at 48 and 72 h post infection (hpi), which was accompanied by an increase in both the number of enriched genes and gene ratio over time (Fig. 2(E)). Cell adhesion molecules (CAMs) are glycoproteins expressed on the cell surface and play crucial roles in a series of biological processes such as maintenance of vascular permeability, immune response, and inflammation (Sarelius & Glading, 2015; Vestweber, 2007). As shown in Fig. 2(F), the differentially expressed genes in this pathway were classified into three groups: HLA class Ⅰ histocompatibility antigens, adhesion-related proteins, and other immune-associated proteins. Most of these proteins were upregulated, including the key adhesion molecule ICAM-1. The transcriptional trends of selected upregulated proteins (ICAM-1 and HLA-B) and downregulated proteins (CLDN11) within this pathway were validated by qRT- PCR, which were consistent with the proteomic data (Fig. S2B). Together, these results confirm the involvement of the cell adhesion pathway, including the upregulation of ICAM-1, and support the use of HUVECs as a relevant in vitro model for studying vascular endothelial responses to CCHFV infection. CCHFV infection promotes adhesion of lymphocytes to vascular endothelial cells The above data suggest a role for the cell adhesion molecules pathway in mediating immune cell adhesion during CCHFV infection. To investigate this potential function, we further evaluated endothelial cell adhesion following viral infection. Using a classical adhesion experimental model, we examined the adhesion between HUVECs and human T lymphocytes (Jurkat cells) under CCHFV-infection conditions. To visualize and quantify adherent cells, we first constructed Jurkat cells stably expressing mCherry (Jurkat-RFP; Fig. S3A and B). For the adhesion assay, HUVECs were seeded in the cell plate and infected with CCHFV-GFP (Li et al., 2025). At 48 h post infection (hpi), Jurkat-RFP cells were added and allowed to adhere for 1 h. Non-adherent cells were removed by washing three times with phosphate-buffered saline (PBS) and the remaining attached Jurkat-RFP cells were visualized (Fig. 3(A)). The results demonstrated that CCHFV infection of HUVECs enhanced the adhesion of Jurkat-RFP cells compared to uninfected controls, despite a detectable level of background adhesion in the latter (Fig. 3(B)). Adhesion was further quantified by measuring the average fluorescent area of attached Jurkat-RFP cells (Fig. 3(B)). To investigate whether the enhanced adhesion was specific to endothelial cells, we repeated the adhesion experiment under the identical conditions using non-endothelial HEK293A (human embryonic kidney cells) and Vero cells (African green monkey kidney cells). In contrast to the results observed in HUVECs, CCHFV infection of 293A and Vero cells did not increase Jurkat-RFP cell adhesion (Figs. S3C, D, F and G). We further detected ICAM1 (encoding ICAM-1) transcriptional levels in all three cell types. CCHFV infection significantly upregulated ICAM1 expression by 5.5-fold in HUVECs (Fig. 3(C)). In contrast, both 293A and Vero cells exhibited substantially lower basal ICAM1 transcription levels compared to HUVECs, and infection induced only a modest upregulation, keeping overall transcription at a low level (Fig. S3E and H). These results demonstrate that the increased adhesion of Jurkat cells is specific to CCHFV-infected endothelial cells and imply that ICAM-1 upregulation is a key factor driving this enhanced adhesion. CCHFV infection of HUVECs induces Jurkat cell adhesion. (A) Schematic diagram of the cell adhesion experiment. (B) Representative fluorescence microscopic images and quantitative analysis results of adhesion experiments in the CCHFV infection group and the mock control group. The green fluorescence indicates the viral infection, and the red fluorescence represents the adherent Jurkat cells. Scale bar, 50 μm. Adhesion level was calculated by normalizing to mock control group and the result represents the fold change of the average fluorescence area of the adherent Jurkat cells. The data were calculated using FIJI on ten fluorescence images from two replicates and expressed as means ± SD. (C) Transcriptional level detection of ICAM1. The expression levels were standardized by GAPDH and compared with the mock control group. Data represents two replicates. Statistical significance was determined using the unpaired two-tailed t-test. ∗P < 0.05; ∗∗∗∗P < 0.000 1. Inhibition of ICAM-1 reduces T cell adhesion induced by CCHFV infection To further investigate the contribution of ICAM-1 to CCHFV-enhanced cell adhesion, we established a stable ICAM1 knockdown HUVEC cell line (sh-ICAM1) and infected it with CCHFV-GFP. qRT-PCR analysis confirmed a significant reduction in ICAM1 transcription (Fig. 4(A)). Unlike control cells (sh-Ctrl), ICAM-1 expression in sh-ICAM1 cells was no longer significantly upregulated following CCHFV infection, further validating the knockdown efficiency (Fig. 4(B)). Subsequently, adhesion assays were performed as outlined in Fig. 3(A). Results demonstrated that knockdown of ICAM1 markedly attenuated the adhesion of Jurkat cells to CCHFV-infected HUVECs (Fig. 4(C) and (D)). Blocking the function of ICAM-1 in HUVECs reduces CCHFV-induced adhesion. (A) The mRNA levels of ICAM1 in the control HUVECs (sh-Ctrl) and ICAM1 knockdown HUVECs (sh-ICAM1) were detected by qRT-PCR. The expression levels were normalized by GAPDH and compared with the control. Data represents two replicates. Statistical significance was determined using the unpaired two-tailed t-test. (B) Protein level measurements were performed to evaluate the efficiency of gene knockdown and to verify the infection status. The expression levels were analyzed by Western blot, using β-actin as an internal control. (C) Representative fluorescence microscopic images of cell adhesion assays (green, viral infection; red, adherent Jurkat cells). (D) Adhesion level was calculated by normalizing to sh-Ctrl (mock) group and the result represents the fold change of the average fluorescence area of the adherent Jurkat cells. The data were calculated using FIJI on ten fluorescence images from two replicates and expressed as means ± SD. Statistical significance was determined using one-way ANOVA, followed by Tukey's multiple comparisons test. (E) SDS-PAGE detection of the expressed extracellular region of ICAM-1 proteins. The result showed that the purified ICAM-1 has a high purity and the expected molecular weight. (F) Measurement of cell viability of HUVECs treated with sICAM-1 by using CCK-8 assay, and the results are expressed as mean ± SD, n = 2. Statistical significance was determined using one-way ANOVA, followed by Tukey's multiple comparisons test. (G) Adhesion levels were normalized to mock control. The data represented ten fluorescence images from two replicates and expressed as means ± SD. Statistical significance was determined using one-way ANOVA, followed by Tukey's multiple comparisons test. (H) Representative fluorescence microscopic images of adhesion experiments. Red, adherent Jurkat cells. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗∗P < 0.0001; ns, not significant. Scale bar, 50 μm. Furthermore, soluble ICAM-1 (sICAM-1) functions as a competitive inhibitor by binding to the integrins on leukocytes (Lee et al., 2010; Meyer et al., 1995), thereby reducing their adhesion to HUVECs. To test this, we expressed and purified the ectodomain of ICAM-1 using a eukaryotic expression system (Fig. 4(E)), and performed adhesion assays. Briefly, HUVECs were seeded and infected with CCHFV-GFP for 48 h. Jurkat-RFP cells were pre-incubated for 30 min with sICAM-1 or control protein bovine serum albumin (BSA), then added to the infected HUVECs and allowed to adhere for 1 h. Non-adherent cells were removed by PBS washing. CCK-8 assay confirmed that sICAM-1 at the concentrations used had no detectable cytotoxicity on HUVECs (Fig. 4(F)). As shown in Fig. 4(G), pre-incubation with sICAM-1 significantly reduced Jurkat-RFP cells adhesion to HUVECs in a dose-dependent manner, and treatment with 800 μg/mL sICAM-1 decreased adhesion by approximately threefold compared to the sICAM-1-free control, lowering adhesion to a level comparable to the non-infected background. Under the same conditions, the control protein (800 μg/mL BSA) showed no significant effect on adhesion. The representative fluorescence images are presented in Fig. 4(H). CCHFV-induced upregulation of ICAM-1 is regulated by NF-κB signaling pathway ICAM-1 transcription is associated with inflammatory signals. Among relevant pathways, the NF-κB pathway serves as a core regulator of adhesion molecule expression, and has been shown in response to various stimuli to drive ICAM-1 promoter activity (Roebuck & Finnegan, 1999). To examine whether CCHFV upregulates ICAM-1 via the NF-κB pathway, we assessed the NF-κB activation. Compared with the mock-infected controls, CCHFV infection promoted nuclear translocation of NF-κB p65 (hereafter referred to as p65) and increased the phosphorylation level of p65, indicating NF-κB activation (Fig. 5(A) and (B)). NF-κB signaling pathway is involved in CCHFV-induced upregulation of ICAM-1. (A) Detection of p65 nuclear translocation. HUVECs were infected with CCHFV-GFP and treated with TPCA-1 (0, 5, 10 μM) throughout infection. Immunostaining was performed with anti-p65 antibody (red). Green, CCHFV infected cells; blue, nuclei (Hoechst 33258). (B) Western blot was used to detect the expression of ICAM-1, CCHFV NP and phosphorylated p65. Mock, uninfected cells. β-actin, loading control. (C) qRT-PCR detection of ICAM1 transcript levels in cells with different treatments. The expression levels were standardized by GAPDH and compared with the mock control. Data are presented as the mean ± SD from three replicates. (D) Representative fluorescence microscopic images of adhesion experiments treated with TPCA-1. Green, CCHFV infection; Red, adherent Jurkat cells. (E) Adhesion level was calculated by normalizing to mock control group and the result represents the fold change of the average fluorescence area of the adherent Jurkat cells. The data were calculated using FIJI on ten fluorescence images from two replicates and expressed as means ± SD. All statistical analyses were performed using one-way ANOVA, followed by Tukey's multiple comparisons test. ∗∗∗∗P < 0.000 1. Scale bar, 50 μm. Furthermore, treatment with the NF-κB pathway inhibitor TPCA-1—a selective inhibitor of IκB kinase-β (IKK-β) —reduced both the nuclear translocation of p65 and phosphorylated p65 levels induced by CCHFV (Fig. 5(A) and (B)). Consistent with this, TPCA-1 significantly suppressed the transcriptional upregulation and protein expression of ICAM-1 (Fig. 5(B) and (C)). Adhesion assays further demonstrated that NF-κB inhibition markedly reversed the increase in CCHFV-induced T cell adhesion (Fig. 5(D) and (E)). Together, these results suggest that CCHFV activates NF-κB signaling, which in turn promotes ICAM-1 transcription and protein expression in HUVECs, thereby enhancing cell adhesion. Blocking ICAM-1/LFA-1 axis with small-molecule drug lifitegrast attenuates the CCHFV-induced cell adhesion Lifitegrast is a FDA-approved small molecule integrin antagonist that acts by blocking the binding of ICAM-1 and LFA-1, thereby inhibiting the lymphocyte-mediated inflammatory cascade (Murphy et al., 2011). To investigate whether lifitegrast could suppress CCHFV-induced cellular adhesion, we performed drug inhibitory experiments. Jurkat-RFP cells were pre-incubated with lifitegrast for 30 min before adding to CCHFV-infected HUVECs for a 1-h adhesion (Fig. 6(A)). A CCK-8 assay confirmed that, within the tested concentration ranges (10, 50, 250, and 1 250 nM), lifitegrast did not affect HUVEC viability (Fig. 6(B)). Subsequent adhesion experiments revealed that lifitegrast significantly reduced the number of adherent Jurkat-RFP cells on infected HUVECs in a dose-dependent manner (Fig. 6(C) and (D)). To exclude the potential impact of lifitegrast on viral infection, we continuously administered the drug as illustrated in Fig. S4A. Measurements of viral protein expression, GFP fluorescence, and viral load in the infection supernatant collectively demonstrated that lifitegrast did not affect viral replication at the concentrations used in the adhesion assays (Fig. S4B–D). Lifitegrast inhibits CCHFV-induced adhesion in a dose-dependent manner. (A) Schematic diagram of the lifitegrast inhibition assay. (B) Measurement of the cytotoxicity of lifitegrast (0, 10, 50, 250, 1 250 nM) by using CCK-8, and the results are expressed as mean ± SD, n = 2. (C) Adhesion levels were normalized to the mock control and the result represents the fold change of the average fluorescence area of the adherent Jurkat cells. The data were calculated using FIJI on ten fluorescence images from two replicates and expressed as means ± SD. (D) Representative fluorescence microscopic images of the adhesion experiments. The red channel represents the adherent Jurkat cells. All statistical analyses were performed using one-way ANOVA, followed by Tukey's multiple comparisons test. ∗∗∗∗P < 0.000 1; ns, not significant. Scale bar, 50 μm. Lifitegrast alleviates CCHFV-induced lethality and tissue pathology in mice The in vivo anti-inflammatory potential of lifitegrast has been demonstrated in prior studies using non-infectious inflammation models (Pabois et al., 2024; Sun et al., 2023). Considering the critical role of inflammatory storm in fatal CCHFV infection, regulating excessive immune activation is likely to be a potential therapeutic approach. However, the effect of lifitegrast in viral infection-related inflammation remains unexplored. To evaluate its potential therapeutic efficacy against CCHFV infection, we synthesized sodium salt of lifitegrast to improve solubility, and conducted an in vivo administration study. Safety was first evaluated in IFNAR−/− mice, which are also used for CCHFV infection experiments. Intraperitoneal injection of lifitegrast sodium at 100 mg/kg (mpk), formulated with 20% (w/v) hydroxypropyl-β-cyclodextrin (HP-β-CD) as the vehicle, showed no detectable in vivo toxicity (Fig. S4E). Subsequently, IFNAR−/− mice were infected with CCHFV-GFP, and treated daily with lifitegrast sodium at 75 mg/kg and 100 mg/kg (Fig. 7(A)). Survival analysis showed that the final survival rate was 16.7% in the vehicle control group, whereas it increased to 50% in the two groups treated with lifitegrast sodium (Fig. 7(B)). Moreover, administration of lifitegrast sodium reduced the average viral load in the target tissue, the liver (Fig. 7(C)). We performed a comprehensive histopathological scoring to evaluate tissue injury. Compared with the vehicle group, the drug-treated group exhibited a general reduction in pathological scores. However, pathological changes in deceased mice within the treatment group remained more severe than those in surviving mice (red circles) from the same group (Fig. 7(D)). Surviving mice in the lifitegrast sodium-treated groups showed significantly alleviated liver injury, with only focal inflammatory cell infiltration (blue arrows). In contrast, deceased mice in the vehicle group displayed marked coagulative necrosis of hepatocytes (dashed white outline) accompanied by extensive inflammatory infiltration (blue arrows) (Fig. 7(E)). Further immunofluorescence analysis revealed widespread viral replication in deceased mice from the vehicle group, whereas viral replication was markedly reduced in surviving mice treated with lifitegrast sodium (Fig. 7(E)). Evaluation of the protective effect of lifitegrast sodium against CCHFV infection in a mouse model. (A)IFNAR−/− mice were infected with CCHFV-GFP (0.01 TCID50) via intraperitoneal injection, followed by daily administration (lifitegrast sodium, 75 and 100 mg/kg, intraperitoneal injection). The vehicle control was given 20%-hydroxypropyl-β-cyclodextrin (HP-β-CD). Mice were sacrificed at ethical endpoint or experimental endpoint. (B) Survival curves of infected mice treated with vehicle, 75 and 100 mg/kg lifitegrast sodium. The dashed line represents the median survival time, n = 6. (C) Detection of viral load in the livers of infected mice. Each dot represents one mouse, and red circles indicate surviving mice. Statistical analysis was performed using Mann-Whitney test, ∗P < 0.05. (D) Semi-quantitative histological scores in liver in three groups. Higher scores indicate more severe pathology. Each symbol represents one animal, and red circles indicate survived mice. Data are presented as mean ± SEM. (E) Histopathological and immunofluorescence detection of a representative mouse. White dashed line, coagulative necrosis of hepatocytes; blue arrows, inflammatory cell infiltration. Immunofluorescence staining was used to label CCHFV NP (red). (F) Transcriptional analysis of inflammatory factors in livers. Relative mRNA levels were measured by qRT-PCR and expressed relative to uninfected control (black dashed line). Each dot represents one mouse; red circles denote survival mice. Data are shown as mean ± SD. Statistical analyses were performed using a one-way nonparametric test followed by Dunn's post hoc multiple comparisons; ns, not significant. (G) Immunofluorescence staining showed the expression of ICAM-1 and the changes of major immune cells in the livers of infected mice, and the green channel indicates cell type markers. Scale bar, 100 μm. Given that cytokine levels correlate with viral load and disease prognosis in CCHFV—where a fatal "cytokine storm" is often implicated (Papa et al., 2006, 2015; Welch et al., 2019), we analyzed the transcription levels of key pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β, encoded by Tnf, Il6 and Il1b) in liver tissues compared to uninfected controls. Lifitegrast sodium treatment attenuated CCHFV-induced upregulation of these cytokines, although the reduction was not statistically significant (Fig. 7(F)). Furthermore, immunofluorescence analysis showed that lifitegrast sodium attenuated vascular activation, as indicated by reduced ICAM-1 expression (Fig. 7(G)). Assessment of immune cell infiltration by immunofluorescence assays demonstrated that lifitegrast sodium also decreased tissue recruitment of T cells, B cells, monocytes, macrophages and neutrophils. The results showed that lifitegrast sodium treatment reduced the tissue infiltration degree of these immune cells (Fig. 7(G)). Discussion Clinical and experimental studies consistently indicate that vascular endothelial activation and barrier dysfunction are common pathological features of hemorrhagic fever viruses (Flórez-Álvarez, 2022; Paessler & Walker, 2013). For instance, Ebola virus (EBOV) directly infects and activates HUVECs, and its glycoproteins independently upregulate ICAM-1, VCAM-1, and E-selectin, thereby enhancing endothelial permeability (Moni et al., 2022; Wahl-Jensen et al., 2005). Dengue virus (DENV) infection in human brain microvascular endothelial cells enhances expression of pro-inflammatory cytokines and ICAM-1 (da Conceição et al., 2013). Similarly, in vitro studies indicate that CCHFV activates HUVECs and upregulates ICAM-1 expression through two pathways: direct infection of HUVECs, or indirect induction via soluble mediators secreted by infected monocyte-derived dendritic cells (moDCs) (Connolly-Andersen et al., 2009, 2011). Clinical studies also provided evidence for CCHFV-induced upregulation of adhesion molecules (Bodur et al., 2010), yet systematic investigations using lethal animal models remain limited and warrant further exploration. In this study, we established a lethal mouse model of CCHFV infection via intravenous injection and demonstrated that CCHFV infects and potently activates vascular endothelial cells in the liver (Fig. 1). Moreover, disruption of endothelial tight junctions was observed, and vascular leakage was confirmed using the EB dye extravasation assay (Fig. S1C and D). These findings further elucidate the characteristics of endothelial cell activation and injury in the CCHFV infection in vivo. To further explore the molecular mechanisms underlying vascular activation, we employed HUVECs as an in vitro model and performed quantitative proteomic analysis to characterize the host response to CCHFV infection. Differentially expressed proteins were significantly enriched in the cell adhesion molecules (CAMs) pathway, which showed the lowest P value among all enriched pathways (Fig. 2(E)). The marked upregulation of the key adhesion molecule ICAM-1 is consistent with the previous observations from in vitro experiments (Fig. 2(F)) (Connolly-Andersen et al., 2011), as well as the animal model used in this study (Fig. 1(C)). Notably, unlike earlier multi-omics studies of CCHFV infection in hepatic cells (Huh-7, HepG2), adrenal cells (SW13), patient-derived PBMCs, or whole blood samples from cynomolgus macaques—which mainly focus on antiviral signaling, cell death and metabolic reprogramming (Arnold et al., 2021; Fraisier et al., 2014; Neogi et al., 2022)—the present work reveals pronounced changes in adhesion molecule expression. To our knowledge, this is the first proteomic investigation conducted in a CCHFV-infected HUVEC model. These results suggest that the endothelial cell response exhibits a distinctive enrichment pattern centered on cell adhesion pathways, indicating that CCHFV infection may trigger vascular activation and inflammatory responses through regulation of the endothelial adhesion interface. Adhesion of leukocytes to activated endothelia acts as an essential prerequisite of inflammatory responses (Butcher, 1991). ICAM-1 upregulation is a marker of vascular endothelial activation, and it mediates the “firm adhesion” of various immune cells through the specific binding to its receptor LFA-1 (Dustin & Springer, 1988; Springer, 1994). Therefore, we focused on this step and investigated the role of ICAM-1 on immune cells adhesion in CCHFV infection. Adhesion assays using Jurkat-RFP/HUVEC demonstrated that the adhesion of T cells to HUVECs was significantly enhanced following CCHFV infection (Fig. 3), which was consistent with a previous report of increased adhesion of isolated leukocytes to CCHFV infected HUVECs (Connolly-Andersen et al., 2011). ICAM-1 may play a similar role in other viral infections; for instance, HIV-1 can upregulate astrocyte ICAM-1 and enhance monocytes adhesion (Song et al., 2011). Moreover, ICAM-1 upregulation has also been observed in hemorrhagic fever viruses such as EBOV and severe fever with thrombocytopenia syndrome (SFTSV), but studies on its role in subsequent adhesion and pathogenesis remains underexplored (Li et al., 2017; Wahl-Jensen et al., 2005). To further investigate the functional role of ICAM-1 in CCHFV-induced cell adhesion, we generated an ICAM1 knockdown HUVEC cell line and performed a soluble ICAM-1 protein blockade assay. The results showed that ICAM1 knockdown did not significantly affect viral infectivity, whereas both approaches markedly inhibited Jurkat cell adhesion triggered by CCHFV infection, underscoring the critical involvement of ICAM-1 in this process (Fig. 4). To investigate the upstream signals of CCHFV-induced ICAM-1 upregulation, we focused on NF-κB, a key transcriptional regulator of ICAM-1 expression. The ICAM-1 promoter contains NF-κB-binding sites, and NF-κB-dependent ICAM-1 induction has been reported in other viral infections such as HIV-1 and DENV (Roebuck & Finnegan, 1999; Yang et al., 2024; Youn et al., 2014). We found that CCHFV infection activates NF-κB, as shown by nuclear translocation and phosphorylation of the p65 subunit. Treatment with the NF-κB inhibitor TPCA-1 reversed this activation, decreased ICAM-1 expression, and reduced cell adhesion, confirming the involvement of NF-κB signaling in this process (Fig. 5). Although our results establish NF-κB activation as essential for ICAM-1 upregulation during CCHFV infection, whether viral components act directly or synergistically in stimulating ICAM-1 remains to be determined. Given the critical role of ICAM-1 in CCHFV-induced cell adhesion, we explored the therapeutic potential of targeting the ICAM-1/LFA-1 axis as an intervention against CCHFV infection. From a screen of inhibitors against this pathway, we selected lifitegrast—the only currently approved small-molecule antagonist of this interaction. Lifitegrast is rationally designed based on the ICAM-1/LFA-1 binding interface; it binds to LFA-1 and competitively blocks its engagement with ICAM-1, thereby suppressing T-cell adhesion and downstream inflammatory signaling (Gadek et al., 2002; Zhong et al., 2010, 2012). This drug has demonstrated notable anti-inflammatory effects in models of ocular inflammation such as keratoconjunctivitis and dry eye disease, and was approved by the FDA for clinical use in 2016 (Murphy et al., 2011; Sheppard et al., 2014; Zhong et al., 2012). It has also been evaluated in models of acute liver injury and Crohn's disease, where it reduced inflammation, suggesting broad anti-inflammatory potential (Pabois et al., 2024; Sun et al., 2023). However, lifitegrast has not previously been evaluated in treating viral infection. Our study represents the first attempt to repurpose lifitegrast to modulate virus-associated immune responses. In vitro, lifitegrast reduced CCHFV-induced adhesion of Jurkat cells to HUVECs in a dose-dependent manner (Fig. 6). Further in vivo studies showed that lifitegrast sodium improved survival in infected mice, mitigated pathological injury in target organs, inhibited immune-related gene expression, and reduced excessive immune cell infiltration in tissues (Fig. 7). These findings support the feasibility of an anti-inflammatory strategy targeting the immune-cell adhesion axis during CCHFV infection. It is worth noting that, in addition to LFA-1, which is broadly expressed on leukocytes, ICAM-1 can also bind to Mac-1 (αMβ2 integrin) and p150,95 (αXβ2 integrin) predominantly expressed on myeloid cells (Kishimoto et al., 1989; Krensky et al., 1983; Nicolls & Gill, 2006; Springer, 1994; Springer & Unkeless, 1984). These interactions may also promote leukocyte adhesion and inflammatory responses during CCHFV infection, a possibility that warrants further investigation. In summary, our findings suggest a model wherein CCHFV infection activates vascular endothelium by upregulating ICAM-1 in an NF-κB–dependent manner, thereby promoting endothelial-T cell adhesion. Functional inhibition of ICAM-1—either by gene knockdown, soluble ICAM-1 competition—effectively suppressed this adhesion response. Notably, the ICAM-1/LFA-1 inhibitor lifitegrast effectively reversed endothelial adhesion and, in a mouse infection model, improved survival while attenuating vascular inflammation and tissue injury. Our findings offer key mechanistic insights into CCHFV-induced vascular activation, and proposing the ICAM-1/LFA-1 axis as a potential broad-spectrum target for anti-inflammatory treatment—not only for CCHFV but potentially for other hemorrhagic fever viruses as well. Materials and methods Ethics statement All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Wuhan Institute of Virology, Chinese Academy of Sciences, and conducted in accordance with ethical requirements in Animal Biosafety Level 3 (ABSL-3) facilities (ethics number: WIVAF01202301). Cells HUVECs (human umbilical vein endothelial cells), HEK293A (adherent subline of human embryonic kidney 293) cells, HEK293T (human embryonic kidney 293 cells expressing the SV40 large T antigen) cells, Vero (African green monkey kidney epithelial) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS). Jurkat cells (human T-lymphocyte cell lines) were cultured in RPMI 1640 medium supplemented with 10% FBS. All cells were grown at 37 °C with 5% CO2. HEK293F cells were propagated in SMM 293-TII Expression Medium (SinoBiological, China) at 37 °C with 8% CO2, shaking at 180 rpm. CCHFV infected lethal mouse model by intravenous injection This study utilized male IFNAR−/− mice (type I interferon receptor–deficient, C57BL/6J background) aged 8-12 weeks (Wang et al., 2022). The mice were thoroughly mixed and randomly divided into groups of 6 animals, and the CCHFV-YL16070 strain (stored at the National Virus Resource Center of China, ID: IVCAS 6.6329) was infected via intravenous injection at a dose of 3 000 TCID50. The symptoms and body weight were monitored daily. Tissue collection was conducted when mice reached a moribund condition (with a weight loss of over 20% or severe ruffled fur and hunched posture). Viral load detection and histopathological analysis were performed as previously described (Zhang et al., 2025). Evans blue dye extravasation assay Mice were treated with Evans blue (EB) dye (20 mg/kg) via intravenous injection, and after circulating for 1 h, cardiac perfusion was performed with approximately 20 mL of phosphate-buffered saline (PBS) as previous described (Xu et al., 2021). Subsequently, a portion of the liver tissues was excised, weighed, and then homogenized thoroughly in RNAiso Plus (TaKaRa, Cat. No. 9109) for pathogen inactivation. Homogenates were centrifuged at 12 000 rpm for 30 min, and the absorbance of the supernatant was determined at 620 nm. Standard curves were prepared using EB dyes diluted with RNAiso Plus at defined concentrations. Quantitative proteomics analysis HUVECs were infected with CCHFV-YL16070 at an MOI of 0.3. Cells were collected using lysis buffer (2% SDS, 100 mM Tris, pH 8.0) at 0, 24, 48 and 72 hpi. Lysates were centrifuged at 12 000 rpm for 15 min, and the supernatant was collected. The experiment was done in duplicate. Proteins were precipitated using trichloroacetic acid (TCA) and reconstituted in 8 M Urea containing 100 mM Tris-HCl (pH 8.5) for quantification by the BCA assay. Reduction and alkylation were performed using tris (2-carboxyethyl) phosphine (TCEP) and chloroacetamide (CAA), followed by enzymatic digestion with trypsin. Mass spectrometry was performed by SpecAlly Life Technology Co., Ltd (Wuhan, China) using the Bruker timsTOF Pro platform, and data were analyzed by DIA-NN (v1.8) software. Differentially expressed proteins (DEPs) were identified based on quantitative data and visualized in R, including volcano plots, KEGG pathway enrichment plots, and heatmaps. Adhesion experiment Stable mCherry-expressing Jurkat (Jurkat-RFP) cells were generated to label adherent cells and achieved by lentiviral transduction of Jurkat cells. Briefly, lentivirus carrying the mCherry expression cassette was packaged in HEK293T cells and used to transduce Jurkat cells, followed by selection with puromycin to establish a stable Jurkat-RFP cell line. Adhesion assays were performed to evaluate adherent Jurkat-RFP cells to HUVECs. HUVECs were seeded at 9 × 104 cells per well in 12-well plate and infected with CCHFV-GFP (CCHFV-IbAr10200-eGFP, National Virus Resource Center of China, ID: CSTR:16533.06; IVCAS6.9295) at an MOI of 0.1. At 48 hpi, Jurkat-RFP cells (4 × 105 cells) were added. After incubation at 37 °C for 1 h, non-adherent cells were removed by washing three times with PBS. Samples were fixed and inactivated with 4% paraformaldehyde for 30 min. Fluorescence images were acquired using an Olympus CKX53 inverted microscope (Olympus, Japan) and analyzed with FIJI software to quantify. The experiment was performed in two replicates. Adhesion assays using HEK293A and Vero cells were conducted following the same procedure described above. Adhesion inhibition assay The adhesion inhibition assay was performed under the same culture and infection conditions as described for the adhesion assay. The following experiment-specific modifications were applied to assess the impact of the various interventions: use of ICAM1 knockdown and corresponding control cells for adhesion assays; preincubation of Jurkat-RFP cells with lifitegrast (MCE, Cat. No. HY-19344) (0, 10, 50, 250 and 1 250 nM, 30 min) before co-culture; preincubation with sICAM-1 (0, 200, 400, 800 μg/mL, 30 min; BSA, control); and addition of NF-κB inhibitor TPCA-1 (MCE, Cat. No. HY-10074) (0, 5, 10 μM) during HUVECs infection. All other procedures and data analysis were performed as described above. Construction of ICAM1 knockdown cells Knockdown of human ICAM1 was achieved by lentiviral transduction of HUVECs. Briefly, HUVECs were infected with lentivirus carrying a specific ICAM1-targeting shRNA sequence for 48 h, followed by selection with puromycin (2 μg/mL) to generate stable ICAM1 knockdown cell line. The target sequence was 5′- GGCTGGAGCTGTTTGAGAACA- 3′. Knockdown efficiency was confirmed by qRT-PCR and quantified using the 2−ΔΔCt method. Expression and purification of recombinant human ICAM-1 The coding sequence corresponding to the extracellular domain of human ICAM-1 was amplified by PCR from HUVEC cDNA (Primers: F, 5′- CGGGGTACCACAGACATCTGTGTCCCCCTC- 3′; R, 5′- CGCGGATCCTCACTCATACCGGGGGGAGAG- 3′). The amplified fragment was cloned into a eukaryotic expression vector containing the human interferon signal peptide sequence and an S-tag to generate the plasmid encoding the extracellular domain of ICAM-1. The recombinant plasmid was transfected into HEK293F cells, and culture supernatants were collected at 4 days post transfection. After clarification by centrifugation, the supernatant was incubated with S-tag affinity beads overnight at 4 °C. Following extensive washing, bound proteins were eluted with 3 M MgCl2 and buffer-exchanged into PBS. The purified protein was analyzed by SDS-PAGE followed by Coomassie Brilliant Blue staining. Cytotoxicity assay Cytotoxicity was assessed using the Cell Counting Kit-8 (MCE, Cat. No. HY-K0301). Briefly, HUVECs were seeded in 96-well plates (1 × 104 cells/well) over night. Cells were exposed to lifitegrast and soluble ICAM-1 (sICAM-1) at the concentrations used in experiments, with vehicle (control) and cell-free (blank) wells run in parallel. After 1 h of treatment, 10 μL CCK-8 reagent was added, followed by 1 h incubation at 37 °C. The absorbance was measured at 450 nm using a Synergy H1 Microplate Reader (BioTek, USA). Viability (%) = (At - Ab)/(Ac - Ab) × 100. At: absorbance of treated wells; Ab: absorbance of blank (cell-free) wells; Ac: absorbance of control (vehicle) wells. Preparation of sodium salt of lifitegrast A stirred solution of lifitegrast (2.0 g, 3.25 mmol) in methanol (10 mL) was treated with a sodium methoxide solution (0.2 g, 3.7 mmol in 10 mL methanol). The reaction mixture was stirred at 50 °C for 1 h. The solvent was removed under reduced pressure, and the residue was stirred with ethyl acetate (10 mL) at 50 °C for 1 h. The solid product was isolated by filtration, washed with ethyl acetate, and dried to yield 1.8 g of lifitegrast sodium as a white solid. Structures were confirmed by 1H NMR, 13C NMR and MS, and purity was verified by HPLC (Data S1). Lifitegrast sodium treatment animal experiment 8-12-week-old male IFNAR−/− mice were infected with CCHFV-GFP at 0.01 TCID50 via intraperitoneal injection. Beginning at 1 hpi, mice received daily intraperitoneal administration of lifitegrast sodium (75 and 100 mg/kg). Control groups received equivalent volumes of vehicle (20% HP-β-CD). Body weight was monitored daily. Mice were euthanized when they became moribund or at the experimental endpoint, and target tissues (liver and spleen) were collected for viral load quantification and histopathological examination as previously described (Zhang et al., 2025). The mRNA expression levels of cytokines in murine liver were determined using relative quantification method described above. Quantitative real-time PCR detection Viral load was determined in infectious supernatants, infected cells and tissue samples. RNA was extracted from culture supernatants, cells and tissues, followed by cDNA generation and viral load quantification, as described previously (Pan et al., 2021; Wang et al., 2020). Relative quantification of gene expression was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems, USA). Ct values were normalized to β-actin (mouse) or GAPDH (human), and relative transcript levels were calculated using the 2−ΔΔCt. Primer sequences used for qRT-PCR analysis in this study are listed in Table S1. Western blot analysis Protein samples were subjected to SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane. Subsequently, the membrane was blocked with 5% non-fat dried milk for 1 h at room temperature, followed by incubation with primary antibodies overnight at 4 °C. After washing with TBS-T (20 mM Tris-base, 150 mM NaCl, 0.05% Tween-20, pH 7.5), the blots were incubated with HRP-conjugated Goat Anti-Mouse/Rabbit IgG (H + L) (Proteintech, Cat. No. SA00001-1/SA00001-2, 1:5 000) for 1 h at room temperature. Signals were detected using SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Cat. No. 34580) and imaged on a MicroChemi system (DNR Bio-Imaging Systems, Israel). The primary antibodies used were as follows: anti-ICAM-1 (Servicebio, Cat. No. GB150141, 1: 1 000), anti-Phospho-NF-κB p65 (S536) (Servicebio, Cat. No. GB113882, 1: 750), anti-β-Actin (Servicebio, Cat. No. GB11001, 1: 2 000). Anti-CCHFV NP (mouse derived anti-NP monoclonal antibody, 1: 5 000) was used as previously described(Li et al., 2024). Immunofluorescence analysis Cells were fixed with 4% (w/v) paraformaldehyde for 30 min, washed with PBS, and permeabilized with 0.2% (v/v) Triton X-100 for 15 min. After blocking with 5% BSA for 1 h at room temperature, cells were incubated with primary antibodies overnight at 4 °C, followed by secondary antibodies for 1 h. Nuclei were stained with Hoechst 33258 (Beyotime, Cat. No. C1018), and images were acquired using an Olympus CKX53 inverted microscope. Tissue immunofluorescence was performed as described previously (Liu et al., 2020). Briefly, paraffin sections were deparaffinized, subjected to antigen retrieval and 0.1% Sudan Black treatment, blocked with 5% BSA for 1 h, incubated with primary antibodies overnight at 4 °C, and then with secondary antibodies for 1 h. Nuclei were stained with Hoechst 33258, and images were acquired using a PANNORAMIC MIDI scanner (3DHISTECH, Hungary) and viewed with SlideViewer software (3DHISTECH). The primary antibodies used were as follows: anti-CD31 (Servicebio, Cat. No. GB11063-2, 1: 500), anti-ICAM-1 (Servicebio, Cat. No. GB11106, 1: 1 000), anti-VCAM-1 (Servicebio, Cat. No. GB113498, 1: 1 000), anti-CD3 (Abcam, Cat. No. ab5690, 1: 100), anti-CD20 (CST, Cat. No. 70168, 1: 400), anti-CD11b (Servicebio, Cat. No. GB11058, 1: 500), anti-CD68 (CST, Cat. No. 97778, 1: 200), anti-Ly6G (Servicebio, Cat. No. GB11229, 1: 200), anti-ZO-1 (Servicebio, Cat. No. GB111981, 1: 400), anti-NF-kB p65/RelA (ABclonal, Cat. No. A19653, 1: 2 000), anti-CCHFV NP (as mentioned above, 1: 500). The second antibodies used in this study were as follows: Alexa Fluor 488/555-conjugated goat anti-rabbit IgG (H&L) (Abcam, Cat. No. ab150077/ab150078), Alexa Fluor 488/555-conjugated goat anti-mouse IgG (H&L) (Abcam, Cat. No. ab150113/ab150114). Statistical analysis Statistical analyses and data visualization were performed with GraphPad Prism (version 10.3.1). Details of statistical tests are provided in the figure legends. CRediT authorship contribution statement Yajie Liu: Writing – original draft, Visualization, Validation, Software, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Liushuai Li: Methodology, Investigation. Kai Liu: Resources. Shuo Chen: Resources. Fan Wu: Investigation. Jiang Li: Resources. Xinbo Zhou: Resources. Zhihong Hu: Writing – review & editing, Supervision, Methodology, Funding acquisition. Wu Zhong: Supervision, Resources, Funding acquisition, Conceptualization. Manli Wang: Writing – review & editing, Supervision, Project administration, Methodology, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments This study was supported by grants the National Natural Science Foundation of China (U22A20336), National Key R&D Program of China (2023YFC2305900), the National Science and Technology Major Projects for “Innovative drugs Research and Development” (2025ZD1803800), and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB0490000). We thank Drs. Yanyi Wang, Yuzhi Fu, Zhisheng Xu, Ke Peng, Shufen Li and Jin Wei for generously providing relevant reagents and valuable advice. We are also grateful to Ding Gao and Juan Min from Center for Instrumental Analysis and Metrology of Wuhan Institute of Virology for their technical assistance. Finally, we acknowledge the technical support provided by the Center for Experimental Animals and BSL-3 laboratories of Wuhan Institute of Virology. Footnotes Supplementary data to this article can be found online at https://doi.org/10.1016/j.cellin.2026.100326. Contributor Information Wu Zhong, Email: zhongwu@bmi.ac.cn. Manli Wang, Email: wangml@wh.iov.cn. Supplementary data The following is the supplementary data to this article: Multimedia component 1 References Associated Data Supplementary Materials Multimedia component 1